(PTCT) PTC Therapeutics - Overview
Stock: Translarna, Emflaza, Upstaza, Evrysdi
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 58.3% |
| Relative Tail Risk | -26.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.15 |
| Alpha | 46.97 |
| Character TTM | |
|---|---|
| Beta | 0.917 |
| Beta Downside | 0.781 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.42% |
| CAGR/Max DD | 0.25 |
Description: PTCT PTC Therapeutics January 11, 2026
PTC Therapeutics (NASDAQ: PTCT) is a U.S.-based biopharma focused on rare-disease medicines, commercializing products such as Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza (Kebilidi) for aromatic L-amino-acid decarboxylase deficiency, Tegsedi and Waylivra for other orphan indications, and Evrysdi for spinal muscular atrophy across pediatric and adult populations.
The pipeline adds Sepiapterin for phenylketonuria, the PTC518 splicing platform targeting Huntington’s disease (in collaboration with Novartis), and inflammation/ferroptosis programs-including vatiquinone for Friedreich’s ataxia-reflecting a strategy of leveraging RNA-based and small-molecule modalities to expand the rare-disease portfolio.
PTC distributes its approved drugs through third-party wholesalers and maintains a network of collaborations with major players such as Roche, Akcea Therapeutics, and Novartis, which provide both development funding and market access leverage.
Key financial metrics (FY 2023) show revenue of roughly $470 million, driven primarily by Evrysdi, and a cash runway of about $350 million, giving the company flexibility to fund late-stage trials without immediate dilution. The rare-disease biotech sector benefits from U.S. orphan-drug incentives (tax credits, market exclusivity) and a growing payer willingness to reimburse high-cost, high-impact therapies, which together underpin PTC’s revenue growth outlook.
Analysts often watch the upcoming PTC518 Phase II readout (expected Q3 2024) as a potential catalyst; a positive signal could materially broaden the company’s addressable market beyond neuromuscular disorders.
For a deeper, data-driven assessment of PTCT’s valuation dynamics, you may find the ValueRay platform’s analyst toolkit useful for building a more granular financial model.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 751.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.26 > 0.02 and ΔFCF/TA 41.32 > 1.0 |
| NWC/Revenue: 64.16% < 20% (prev 74.48%; Δ -10.32% < -1%) |
| CFO/TA 0.27 > 3% & CFO 715.5m > Net Income 751.7m |
| Net Debt (1.82b) to EBITDA (911.8m): 2.00 < 3 |
| Current Ratio: 2.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (87.1m) vs 12m ago 13.25% < -2% |
| Gross Margin: 91.20% > 18% (prev 0.84%; Δ 9037 % > 0.5%) |
| Asset Turnover: 79.32% > 50% (prev 48.89%; Δ 30.43% > 0%) |
| Interest Coverage Ratio: 6.37 > 6 (EBITDA TTM 911.8m / Interest Expense TTM 138.1m) |
Altman Z'' 0.92
| A: 0.43 (Total Current Assets 2.01b - Total Current Liabilities 866.2m) / Total Assets 2.64b |
| B: -1.07 (Retained Earnings -2.83b / Total Assets 2.64b) |
| C: 0.39 (EBIT TTM 879.1m / Avg Total Assets 2.24b) |
| D: -1.01 (Book Value of Equity -2.82b / Total Liabilities 2.80b) |
| Altman-Z'' Score: 0.92 = BB |
Beneish M -2.91
| DSRI: 0.51 (Receivables 203.1m/200.0m, Revenue 1.78b/900.7m) |
| GMI: 0.92 (GM 91.20% / 83.63%) |
| AQI: 0.79 (AQ_t 0.19 / AQ_t-1 0.24) |
| SGI: 1.98 (Revenue 1.78b / 900.7m) |
| TATA: 0.01 (NI 751.7m - CFO 715.5m) / TA 2.64b) |
| Beneish M-Score: -2.91 (Cap -4..+1) = A |
What is the price of PTCT shares?
Over the past week, the price has changed by -1.77%, over one month by -2.42%, over three months by +10.23% and over the past year by +49.73%.
Is PTCT a buy, sell or hold?
- StrongBuy: 7
- Buy: 3
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the PTCT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 88.5 | 18.2% |
| Analysts Target Price | 88.5 | 18.2% |
| ValueRay Target Price | 82.7 | 10.4% |
PTCT Fundamental Data Overview February 02, 2026
P/E Forward = 6.006
P/S = 3.4085
P/B = 1743.2734
P/EG = 0.81
Revenue TTM = 1.78b USD
EBIT TTM = 879.1m USD
EBITDA TTM = 911.8m USD
Long Term Debt = 2.11b USD (from longTermDebt, last fiscal year)
Short Term Debt = 561.4m USD (from shortTermDebt, last quarter)
Debt = 2.49b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.82b USD (from netDebt column, last quarter)
Enterprise Value = 6.85b USD (6.06b + Debt 2.49b - CCE 1.71b)
Interest Coverage Ratio = 6.37 (Ebit TTM 879.1m / Interest Expense TTM 138.1m)
EV/FCF = 9.80x (Enterprise Value 6.85b / FCF TTM 699.0m)
FCF Yield = 10.21% (FCF TTM 699.0m / Enterprise Value 6.85b)
FCF Margin = 39.29% (FCF TTM 699.0m / Revenue TTM 1.78b)
Net Margin = 42.25% (Net Income TTM 751.7m / Revenue TTM 1.78b)
Gross Margin = 91.20% ((Revenue TTM 1.78b - Cost of Revenue TTM 156.5m) / Revenue TTM)
Gross Margin QoQ = 45.05% (prev 93.62%)
Tobins Q-Ratio = 2.59 (Enterprise Value 6.85b / Total Assets 2.64b)
Interest Expense / Debt = 1.31% (Interest Expense 32.6m / Debt 2.49b)
Taxrate = 21.0% (US default 21%)
NOPAT = 694.5m (EBIT 879.1m * (1 - 21.00%))
Current Ratio = 2.32 (Total Current Assets 2.01b / Total Current Liabilities 866.2m)
Debt / Equity = -16.00 (negative equity) (Debt 2.49b / totalStockholderEquity, last quarter -155.8m)
Debt / EBITDA = 2.00 (Net Debt 1.82b / EBITDA 911.8m)
Debt / FCF = 2.60 (Net Debt 1.82b / FCF TTM 699.0m)
Total Stockholder Equity = -411.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 33.51% (Net Income 751.7m / Total Assets 2.64b)
RoE = -182.7% (negative equity) (Net Income TTM 751.7m / Total Stockholder Equity -411.5m)
RoCE = 51.78% (EBIT 879.1m / Capital Employed (Equity -411.5m + L.T.Debt 2.11b))
RoIC = 175.9% (NOPAT 694.5m / Invested Capital 394.8m)
WACC = 6.89% (E(6.06b)/V(8.56b) * Re(9.30%) + D(2.49b)/V(8.56b) * Rd(1.31%) * (1-Tc(0.21)))
Discount Rate = 9.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.41%
[DCF Debug] Terminal Value 76.68% ; FCFF base≈699.0m ; Y1≈485.8m ; Y5≈248.4m
Fair Price DCF = 51.86 (EV 5.98b - Net Debt 1.82b = Equity 4.16b / Shares 80.3m; r=6.89% [WACC]; 5y FCF grow -35.75% → 2.90% )
[DCF Warning] FCF declining rapidly (-35.75%), DCF may be unreliable
EPS Correlation: 59.67 | EPS CAGR: 30.77% | SUE: 0.07 | # QB: 0
Revenue Correlation: 42.75 | Revenue CAGR: 6.74% | SUE: 0.12 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.68 | Chg30d=+0.410 | Revisions Net=-2 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.91 | Chg30d=-0.074 | Revisions Net=-1 | Growth EPS=-109.5% | Growth Revenue=-47.1%